MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
1 other identifier
observational
3,000
1 country
1
Brief Summary
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict molecular pathology or subgroups of gliomas.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
December 30, 2019
CompletedFirst Posted
Study publicly available on registry
January 3, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
February 8, 2021
February 1, 2021
10 years
December 30, 2019
February 5, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
AUC of prediction performance
AUC=sensitivity+specificity-1
up to 10 years
Interventions
Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
Eligibility Criteria
Patients with newly diagnosed glioma that receive tumor resection
You may qualify if:
- Patients must have radiologically and histologically confirmed diagnosis of primary glioma
- Life expectancy of greater than 3 months
- Must receive tumor resection
- Signed informed consent
You may not qualify if:
- No gliomas
- No sufficient amount of tumor tissues for detection of molecular pathology
- Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices
- Patients who are pregnant or breast feeding
- Patients who are suffered from severe systematic malfunctions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
Related Publications (1)
Liu Z, Hong X, Wang L, Ma Z, Guan F, Wang W, Qiu Y, Zhang X, Duan W, Wang M, Sun C, Zhao Y, Duan J, Sun Q, Liu L, Ding L, Ji Y, Yan D, Liu X, Cheng J, Zhang Z, Li ZC, Yan J. Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas. BMC Cancer. 2023 Sep 11;23(1):848. doi: 10.1186/s12885-023-11338-8.
PMID: 37697238DERIVED
Biospecimen
All participants have signed the informed consent. Fresh frozen tissues of participants are collected immediately after tumor resection and preserved in liquid nitrogen. Whole exome sequencing, RNA sequencing and proteomics are planed to be conducted.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 120 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 30, 2019
First Posted
January 3, 2020
Study Start
January 1, 2017
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
February 8, 2021
Record last verified: 2021-02